Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Byol Shin

Allergy & Immunology Lawrenceville, GA Doctor of Osteopathy

NPI 1669680401 CMS profile 467990

1740 Lawrenceville Hwy, Lawrenceville, GA 30044

Open in the dashboard

General payments

$11,975

547 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Byol Shin of Lawrenceville, GA is reported in the CMS Open Payments database as having received $11,975 across 547 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,522 118
2024 General $1,844 95
2023 General $1,937 93
2022 General $1,563 94
2021 General $1,660 72
2020 General $1,753 49
2019 General $695 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Byol Shin
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Byol Shin were reported at $2,522. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Byol Shin Allergy & Immunology median Middle half National median
2019 $695 $594 $163–$1,512 $163
2020 $1,753 $426 $106–$1,233 $114
2021 $1,660 $638 $157–$1,708 $132
2022 $1,563 $790 $205–$1,961 $149
2023 $1,937 $852 $220–$2,147 $160
2024 $1,844 $865 $203–$2,267 $164
2025 $2,522 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $1,523 46 payments
  2. AstraZeneca Pharmaceuticals LP $1,505 74 payments
  3. OptiNose US, Inc. $1,091 18 payments
  4. GlaxoSmithKline, LLC. $1,041 56 payments
  5. AbbVie, Inc. $966 67 payments
  6. Amgen Inc. $850 51 payments
  7. Regeneron Healthcare Solutions, Inc. $719 30 payments
  8. CSL Behring $505 26 payments
  9. Grifols USA, LLC $305 17 payments
  10. Novartis Pharmaceuticals Corporation $302 15 payments
  11. Other $3,166 147 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,439 535 payments
  2. Consulting Fee $892 4 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $350 1 payment
  4. Education $294 7 payments
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $1,784 63 payments
  2. Xhance $1,091 18 payments
  3. RINVOQ $1,002 68 payments
  4. TEZSPIRE Inflammation $777 48 payments
  5. DUPIXENT Inflammation And Immunology $555 23 payments
  6. TEZSPIRE Respiratory $534 20 payments
  7. FASENRA $524 26 payments
  8. NUCALA $522 25 payments
  9. Hizentra $358 18 payments
  10. TRELEGY ELLIPTA $329 20 payments
  11. Other $4,979 246 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

661

Median for Allergy/ Immunology: 449

Drug cost

$353,372

Median for Allergy/ Immunology: $169,700

Branded share of claims

41.9%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 43 $158,668
Dupixent Syringe Dupilumab Brand 32 $118,923
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 61 $43,013
Breo Ellipta Fluticasone/Vilanterol Brand 30 $18,036
Symbicort Budesonide/Formoterol Fumarate Brand 28 $6,413
Ventolin Hfa Albuterol Sulfate Brand 39 $2,496
Ipratropium Bromide Generic 51 $1,591
Albuterol Sulfate Hfa Albuterol Sulfate Brand 44 $1,073
Fluticasone Propionate Generic 78 $859
Azelastine Hcl Generic 41 $832

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$26,506

Medicare's payments for the services billed

Medicare patients

137

Average age 73

Services billed

1,651

92 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 36%
Osteoporosis 30%
COPD 26%
Ischemic heart disease 22%
Chronic kidney disease 14%
Heart failure 12%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $372
$372 — —
TEZSPIRE
  • Amgen Inc. $224
  • AstraZeneca Pharmaceuticals LP $59
$283 — —
DUPIXENT
  • GENZYME CORPORATION $190
  • Regeneron Healthcare Solutions, Inc. $88
$278 75 —
NUCALA
  • GlaxoSmithKline, LLC. $183
$183 — —
YUPELRI
  • Mylan Specialty L.P. $151
$151 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

547 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record